Condition
Amyloidosis in Transthyretin (TTR)
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Completed1
Not Yet Recruiting1
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07213297RecruitingPrimary
Comprehensive Program for Hereditary Transthyretin Amyloidosis
NCT07116473Phase 3Not Yet RecruitingPrimary
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07080268Active Not RecruitingPrimary
Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.
NCT01623245Completed
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Showing all 4 trials